ArticleThe Lancet. Rheumatology2020
Iloprost for COVID-19-related vasculopathy.
Article in The Lancet. Rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Prostacyclin in Intubated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized Clinical Trial.American journal of respiratory and critical care medicine · 2022Trial
- Platelet-Activating Factor Promotes Neutrophil Activation and Platelet-Neutrophil Complex Formation.Scandinavian journal of immunology · 2025Article
- Management of COVID-19 in Patients with Pulmonary Arterial Hypertension.Heart failure clinics · 2023Review
- Article
- Compassionate use of Pulmonary Vasodilators in Acute Severe Hypoxic Respiratory Failure due to COVID-19.Journal of intensive care medicine · 2022Article
- Systemic sclerosis in the time of COVID-19.The Lancet. Rheumatology · 2022Review
- Inhaled pulmonary vasodilators in severe COVID-19: Don't hold your breath.Journal of critical care · 2022Article
- Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19.Advances in biological regulation · 2021Review
- Inhaled iloprost improves gas exchange in patients with COVID-19 and acute respiratory distress syndrome.Critical care (London, England) · 2021Article
- Recognition and treatment of devastating vasculopathic systemic disorders: Coronavirus disease 2019 and rickettsioses.Dermatologic therapy · 2021Review
- COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic.Journal of scleroderma and related disorders · 2021Review
- Iloprost in COVID-19: The Rationale of Therapeutic Benefit.Frontiers in cardiovascular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.